Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant EC-T vs ET-X in Node-Positive Breast Cancer
NCT00129935Phase 3Completed
- Sponsor
- GEICAM
- Start
- Feb 2004
- Primary completion
- Jun 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in breast cancer, sponsored by GEICAM. Primary endpoint: Disease-free Survival at 5 years. Started Feb 2004; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00129935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129935.